SCYNEXIS Inc Announces FDA Approval of Brexafemme As The First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections Corporate Call Transcript
Greetings, and welcome to the SCYNEXIS post-approval investor call for BREXAFEMME. (Operator Instructions)
As a reminder, this conference is being recorded.
I'd now like to turn the conference over to your host, Ms. Irina Koffler with LifeSci Advisors. Thank you. You may begin.
Good morning, and thank you for joining us as we provide a key corporate update on the FDA approval of BREXAFEMME for the treatment of VVC. Joining me today from SCYNEXIS are Dr. Marco Taglietti, President and Chief Executive Officer; Dr. David Angulo, Chief Medical Officer; and Christine Coyne, Chief Commercial Officer.
During this call, please note, we will be making forward-looking statements. These statements are subject to factors, risks and uncertainties, including those that are detailed in today's presentation and our Form 10-K for the year ended December 31, 2020, as well as our subsequent SEC filings that may cause actual results to differ materially from those results expressed or advised by such statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
